Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome | Zendy

Jonathon Truwit | Zendy; Gordon R. Bernard | Zendy; Jay S. Steingrub | Zendy; Michael A. Matthay | Zendy; Kathleen D. Liu | Zendy; Timothy E. Albertson | Zendy; Roy G. Brower | Zendy; Carl Shanholtz | Zendy; Peter Rock | Zendy; Ivor S. Douglas | Zendy; Bennett P. deBoisblanc | Zendy; Catherine L. Hough | Zendy; R. Duncan Hite | Zendy; B. Taylor Thompson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome

Author(s) -

Jonathon Truwit,

Gordon R. Bernard,

Jay S. Steingrub,

Michael A. Matthay,

Kathleen D. Liu,

Timothy E. Albertson,

Roy G. Brower,

Carl Shanholtz,

Peter Rock,

Ivor S. Douglas,

Bennett P. deBoisblanc,

Catherine L. Hough,

R. Duncan Hite,

B. Taylor Thompson

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1401520

Subject(s) - medicine , rosuvastatin , ards , sepsis , placebo , intensive care unit , rosuvastatin calcium , lung , alternative medicine , pathology

In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes in critically ill patients with sepsis-associated ARDS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research